These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29952537)

  • 1. [In process].
    Verspohl EJ
    Med Monatsschr Pharm; 2017 Jan; 40(1):40. PubMed ID: 29952537
    [No Abstract]   [Full Text] [Related]  

  • 2. Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis.
    Bourdette D; Hartung D
    JAMA Neurol; 2015 Dec; 72(12):1411-3. PubMed ID: 26457848
    [No Abstract]   [Full Text] [Related]  

  • 3. Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?
    Sørensen PS
    Nat Rev Neurol; 2016 Jan; 12(1):5-6. PubMed ID: 26635211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis disease-modifying therapy and pregnancy.
    Miller AE
    Mult Scler; 2016 May; 22(6):715-6. PubMed ID: 27207870
    [No Abstract]   [Full Text] [Related]  

  • 5. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
    Garattini L; Ghislandi F; Da Costa MR
    Pharmacoeconomics; 2015 Dec; 33(12):1241-4. PubMed ID: 26293887
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis.
    Kuerten S; Jackson LJ; Kaye J; Vollmer TL
    CNS Drugs; 2018 Nov; 32(11):1039-1051. PubMed ID: 30315499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Bourgeois F
    Rev Infirm; 2016 Mar; (219):45-6. PubMed ID: 26944649
    [No Abstract]   [Full Text] [Related]  

  • 9. Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate.
    Krečak I; Celić-Bunikić S; Skelin M; Lucijanić M; Verstovsek S; Kušec R
    Ann Hematol; 2022 Aug; 101(8):1885-1886. PubMed ID: 35461396
    [No Abstract]   [Full Text] [Related]  

  • 10. Demonstration of equivalence of a generic glatiramer acetate (Glatopa™).
    Anderson J; Bell C; Bishop J; Capila I; Ganguly T; Glajch J; Iyer M; Kaundinya G; Lansing J; Pradines J; Prescott J; Cohen BA; Kantor D; Sachleben R
    J Neurol Sci; 2015 Dec; 359(1-2):24-34. PubMed ID: 26671082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
    Tsareva E; Kulakova O; Boyko A; Favorova O
    Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emergence of follow-on disease-modifying therapies for multiple sclerosis.
    Moss BP; Cohen JA
    Mult Scler; 2019 Oct; 25(12):1560-1565. PubMed ID: 31074707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
    Duddy M; Palace J
    Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.
    Weiner HL
    Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3333-5. PubMed ID: 10097037
    [No Abstract]   [Full Text] [Related]  

  • 15. Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes.
    Borchard G; Crommelin DJA
    Expert Opin Drug Deliv; 2018 Mar; 15(3):247-259. PubMed ID: 29241378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    J Neurol; 2000 Sep; 247(9):713. PubMed ID: 11081814
    [No Abstract]   [Full Text] [Related]  

  • 17. Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate.
    D Alessandro J; Garofalo K; Zhao G; Honan C; Duffner J; Capila I; Fier I; Kaundinya G; Kantor D; Ganguly T
    CNS Neurol Disord Drug Targets; 2017; 16(6):714-723. PubMed ID: 28240190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spasticity in multiple sclerosis and role of glatiramer acetate treatment.
    Meca-Lallana JE; Hernández-Clares R; Carreón-Guarnizo E
    Brain Behav; 2015 Sep; 5(9):e00367. PubMed ID: 26445705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis.
    Valenzuela RM; Kaufman M; Balashov KE; Ito K; Buyske S; Dhib-Jalbut S
    J Neuroimmunol; 2016 Nov; 300():59-65. PubMed ID: 27390072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).
    Losy J; Michałowska-Wender G; Kurdyńska A; Wender M
    Folia Neuropathol; 2005; 43(3):153-5. PubMed ID: 16245210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.